博文

Restart cell-metabolism first by a reworked aconitase , 2

已有 586 次阅读 2026-9-13 23:43 |个人分类:细胞代谢疗法|系统分类:观点评述

To be continued

The Master Switch of Metabolic Disease and Inflammaging: Excess ROS Inhibits Aconitase, Leading to Acetyl-CoA Overproduction, Which in Turn Drives Both Insulin Resistance and Inflammaging — A Unified Mechanistic Hypothesis linking High-Calorie, High-Carbohydrate, High-Fat Diet, Physical Inactivity, and Micronutrient Deficiency to Metabolic Disease and Pathological Aging

An Exploratory Framework Based on Integrated Intervention with Calorie control, MRD, MLCT, and Micronutrients

V. Design Logic of the Integrated Intervention Plan

Based on the above hypothesis, a reasonable intervention strategy should satisfy the following conditions:

Reduce oxidative attack on aconitase (lower ROS)
Support the repair and regeneration of aconitase (provide cofactors and structural raw materials)
Reduce the pressure of citrate accumulation and SLC25A1 efflux
Act simultaneously on both branches to avoid favoring one over the other

The following plan is a combination of five intervention approaches designed to validate this hypothesis. At this stage, it should be regarded as an exploratory toolkit, not a confirmed standardized treatment:

5.1 Caloric Control and Time-Restricted Eating

Target: Reduce substrate load on the electron transport chain, decrease electron leakage and basal ROS production.
Implementation: Moderate caloric deficit (daily -15% to -25%) combined with time-restricted eating (8–10 hour window).
Support: Studies such as Cell Metabolism (2012) have confirmed that time-restricted eating can improve liver circadian clock rhythm and glucose-lipid metabolism without relying on weight loss.

5.2 Methionine Restriction (MRD)

Target: Reduce SAM supply, decrease pro-inflammatory/pro-insulin resistance pressure at the epigenetic level, and simultaneously alleviate secondary attack of homocysteine on iron-sulfur clusters.
Implementation: Daily methionine intake controlled at 450–500 mg (60 kg adult), achieved through precise supply of low-methionine recombinant food protein (<0.15%).
Support: Cell Metabolism (2021), Nature Metabolism (2024), etc.

5.3 Medium-Chain Fatty Acids (MCT/MLCT)

Target: MCT rapidly oxidizes to produce ketones; BHB possesses multiple functions including NLRP3 inflammasome inhibition (Nature, 2019), HDAC inhibition, and PAK1 signaling downregulation, which can directly suppress branch two.
Implementation: 15%–30% of daily energy intake, taken in divided doses with meals.

5.4 Resistant Starch (RS4)

Target: Repair the intestinal barrier, reduce LPS entry into the bloodstream, and decrease TLR4/NF-κB pathway-mediated transcriptional downregulation of aconitase.
Implementation: Daily supplementation of 30–40 g RS4-type resistant starch.
Support: Nature Metabolism (2024), etc.

5.5 Mitochondrial Micronutrient Package

Target: Provide cofactors for [4Fe-4S] cluster regeneration, cardiolipin repair, and antioxidant enzyme systems (GPX4, SOD2).
Ingredients: Reduced coenzyme Q10 (200 mg), α-lipoic acid (600 mg), NAC (600 mg), benfotiamine (50 mg), magnesium glycinate (300–600 mg elemental magnesium), zinc picolinate (30 mg), selenomethionine (200 μg), etc.

VI. Verifiability: How to Test This Hypothesis and Plan?

For experts, the persuasiveness of any hypothesis ultimately depends on its verifiability. This plan provides three levels of testable endpoints:

Level One: Mechanistic Validation (Cell/Animal Models)

In metabolic stress models, detect whether the decrease in aconitase activity precedes the increase in SLC25A1 efflux
Through aconitase gene knockout/knockdown, observe whether citrate accumulation and SASP gene expression directly increase
After applying this plan, detect whether restoration of aconitase activity correlates with reversal of FGF21/SASP

Level Two: Human Biomarker Tracking (Clinical Observation)

Monitoring Level	Specific Indicators	Reflected Target
Reductive stress	Lactate/pyruvate ratio, β-hydroxybutyrate/acetoacetate ratio	NADH/NAD⁺ ratio status
Mitochondrial stress	Plasma FGF21, FABP4	Mitochondrial stress and fatty acid metabolism status
Aconitase-related	Serum aconitase activity (research-grade), urinary citrate	First target activity and citrate accumulation
Branch A (insulin resistance)	HOMA-IR, OGTT insulin release curve	Degree of IRS-1 signaling recovery
Branch B (inflammaging)	Plasma IL-6, IL-8, TNF-α, hsCRP	SASP transcriptional activity

Level Three: Clinical Endpoints (Long-Term Follow-Up)

Blood glucose reversal rate in prediabetic populations
Drug reduction status in type 2 diabetes patients
Changes in frailty index and cognitive function in elderly populations

VII. From Mechanism to Market: Potential Pathways for Industrial Translation

7.1 Product Formats (Exploratory Stage)

Product TierFormatTarget PopulationResearch-Grade (Mechanism Validation)Low-methionine recombinant protein (<0.15%) + MLCT structured lipids + RS4 + Micronutrient combinationsIIT clinical research; Real-world data accumulationMedical-Grade (FSMP)Same as above; Completed FSMP registrationPatients with diagnosed metabolic diseases, precancerous lesions, or post-operative recurrence preventionConsumer-Grade (Functional Food)Micronutrient packages + RS4 + MCT oilHigh-net-worth health management populations; Individuals at high metabolic risk

7.2 Key Questions to Address for Industrialization

Long-term adherence and tolerability data.
Individual variations and response predictions across different metabolic genotypes.
Drug-drug interactions with existing medications (e.g., metformin, GLP-1 agonists, SGLT2 inhibitors).
Cost-effectiveness analysis and health insurance reimbursement models.

VIII. Conclusion: A Hypothesis to Be Validated, A Direction Worth Exploring

The vulnerability of aconitase, the pathological shunting of citrate efflux, and the two resulting pathogenic pathways provide a unified framework for understanding insulin resistance and inflammaging from the metabolic ground up. Whether this framework holds true ultimately requires repeated validation through cellular models, animal experiments, and clinical observations. However, its value lies in linking multiple independent molecular discoveries—reductive stress and NADH accumulation, iron-sulfur cluster oxidative damage, TCA cycle congestion, SLC25A1/ACLY-mediated acetyl-CoA generation, DAG-induced insulin resistance, and histone acetylation-driven SASP—into a causally logical chain, thereby providing clear biological targets for integrated interventions.

It is particularly worth emphasizing that within the entire metabolic network spanning from glycolysis to the TCA cycle and the electron transport chain, aconitase serves as the "primary target" for ROS attacks due to the unique structure of its [4Fe-4S] cluster. This is driven by the solvent exposure of the Feα site, an exceptionally high reaction rate with superoxide anions (~10⁷ M⁻¹s⁻¹), and a significant decrease in the thermal stability of the oxidized [3Fe-4S]⁺ state. Although enzymes such as GAPDH, PDH, OGDH, and SDH are similarly sensitive to ROS, they are all temporally secondary to aconitase.

Whether this exploration can be translated into effective clinical tools and industrial products depends on subsequent data accumulation and collaboration with venture capital. At the very least, it currently offers a pathway that deserves serious consideration: the treatment of metabolic diseases may need to shift from "managing downstream output metrics" to "repairing upstream metabolic nodes," with aconitase serving as an unavoidable starting point in this paradigm shift.

References

Mercola J, et al. Reductive stress and mitochondrial dysfunction: The hidden link in chronic disease. Free Radical Biology and Medicine. 2025;233:118-131.
Castro L, Tórtora V, Mansilla S, Radi R. Aconitases: Non-redox Iron-Sulfur Proteins Sensitive to Reactive Species. Accounts of Chemical Research. 2019;52(9):2609-2619.
Scandroglio F, Tórtora V, Radi R, Castro L. Metabolic control analysis of mitochondrial aconitase: influence over respiration and mitochondrial superoxide and hydrogen peroxide production. Free Radical Research. 2014;48(6):684-693.
Mansilla S, et al. Redox sensitive human mitochondrial aconitase and its interaction with frataxin: In vitro and in silico studies confirm that it takes two to tango. Free Radical Biology and Medicine. 2023;198:107-120.
Lushchak OV, et al. Aconitase post-translational modification as a key in linkage between Krebs cycle, iron homeostasis, redox signaling, and metabolism of reactive oxygen species. Redox Report. 2014;19(1):8-15.
Tabatabaie T, Potts JD, Floyd RA. Reactive oxygen species-mediated inactivation of pyruvate dehydrogenase. Archives of Biochemistry and Biophysics. 1996;336(2):290-296.
Tretter L, Adam-Vizi V. Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philosophical Transactions of the Royal Society B. 2005;360(1464):2335-2345.
Baillie JKS, et al. Electron Transport Chain - TCA cycle enzymes are vulnerable to oxidative stress. ScienceDirect. 2024.
The writers, readers, and erasers in redox regulation of GAPDH. Antioxidants & Redox Signaling. 2020.
Baillie JKS, et al. ROS inhibits multiple glycolytic enzymes, including GAPDH, PKM2, and PFK-1. Springer.
Baillie JKS, et al. SDH and aconitase (ACN) rely on the presence of [4Fe-4S]²⁺ clusters. ScienceDirect.
Baillie JKS, et al. Lipoic acid residues of OGDH and PDH are prime targets of ROS toxicity. ScienceDirect.
Baillie JKS, et al. NO attenuates glycolysis via inhibitory S-nitrosylation of GAPDH. PMC. 2021.
Palma FR, et al. The Writers, Readers, and Erasers in Redox Regulation of GAPDH. Antioxidants. 2020.
Hurd TR, et al. Inactivation of pyruvate dehydrogenase kinase 2 by mitochondrial reactive oxygen species. J Biol Chem. 2012;287(42):35153-35160.
Tretter L, Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of α-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci. 2000;20(24):8972-8979.
Baillie JKS, et al. Itaconate can competitively inhibit SDH, leading to succinate accumulation. ScienceDirect.
Baillie JKS, et al. PDH and OGDH are inhibited under oxidative stress conditions. ScienceDirect.